• Mutation; HGNC; HGNC:11110; ARID1A; Simple; p.Glu1108Ter (c.3322G>T); Zygosity=Heterozygous (PubMed=30737244).
  
• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30733375; PubMed=30737244).
  
• Mutation; HGNC; HGNC:5382; IDH1; Simple; p.Arg132Leu (c.395G>T); ClinVar=VCV000375889; Zygosity=Heterozygous (PubMed=30737244).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Cys135Trp (c.405C>G); ClinVar=VCV000376561; Zygosity=Homozygous (PubMed=30733375; PubMed=30737244).
  

PubMed=23833040; DOI=10.1210/jc.2013-2383; PMCID=PMC3763971
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=30733375; DOI=10.1158/1541-7786.MCR-18-1026; PMCID=PMC6711777
Schweppe R.E., Pozdeyev N., Pike L.A., Korch C.T., Zhou Q., Sams S.B., Sharma V., Pugazhenthi U., Raeburn C.D., Albuja-Cruz M.B., Reigan P., LaBarbera D.V., Landa-Lopez I., Knauf J.A., Fagin J.A., Haugen B.R.
Establishment and characterization of four novel thyroid cancer cell lines and PDX models expressing the RET/PTC1 rearrangement, BRAFV600E, or RASQ61R as drivers.
Mol. Cancer Res. 17:1036-1048(2019)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280
Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)